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..1. Introduction
Athletic training is associated with a spectrum of morphologic and
functional cardiac adaptations known as ‘the athlete’s heart’.1,2 To
the purpose of the present document an athlete is defined as an indi-
vidual of young or adult age, either amateur or professional, who is
engaged in regular exercise training and participate in official sports
competition. Official sports competition is defined as an organized
team or individual sports event that place a high premium on athletic
excellence and achievement and is organized and scheduled in the
agenda of Athletic Associations.3
A vast amount of literature has been assembled over the last two
decades improving our understanding of the characteristics of physio-
logic cardiac remodelling in athletes. However, there are still areas of
uncertainty regarding the differential diagnosis of the most marked
expression of the athlete’s heart, with certain inherited cardiac dis-
eases, such as hypertrophic (HCM), dilated (DCM), or arrhythmo-
genic cardiomyopathy (AC) and left ventricular non-compaction
(LVNC) cardiomyopathy.4–7
Indeed, in the more recent times, advances in technology,
including three-dimensional (3D) echocardiography, speckle tracking
echocardiography (STE), cardiac magnetic resonance (CMR), and
multi-detector computed tomography (CT) have largely improved the
diagnostic capabilities of the modern imaging modalities and made pos-
sible the correct identification of a broader spectrum of pathologic car-
diovascular conditions that might occur in the athlete’s population.
In 2015, an initial effort has been carried out by the European
Association of Cardiovascular Imaging (EACVI) in order to guide
appropriate interpretation of imaging in the context of athletes’ evalua-
tion.8 After the initial interest raised by this document, further advances
have been carried out in this field, including new international criteria
for electrocardiogram (ECG) interpretation, updated recommenda-
tions for sport eligibility from the American College of Cardiology and
American Heart Association, and further research in this field.9–16
Therefore, we believed it timely and appropriate to expand pre-
vious work and assemble a novel recommendation document with
combined effort of experts from both the European Association of
Preventive Cardiology (EAPC) and EACVI in order to properly
address the determinants of cardiac remodelling, indications for imag-
ing and clues for differential diagnosis with cardiac pathology. In addi-
tion, in this revised document we addressed number of pathologic
conditions that are relevant to the cardiovascular evaluation of the
athletes (and were not included in previous document), such as left-
ventricular non-compaction, myocarditis, mitral valve prolapse, and
bicuspid aortic valve (BAV).
2 Cardiovascular adaptations in
athletes
2.1 Impact of gender, age, race, and body
size
The quest for excellence in sports is associated with a plethora of
electrical, structural and functional cardiac adaptations termed the
‘athlete’s heart’. Manifestations of the athlete’s heart include a higher
prevalence of electrocardiographic anomalies, balanced increase in the
left and right cardiac cavity sizes, increased left ventricular (LV) wall
thickness and superior indices of systolic and diastolic function, com-
pared with sedentary individuals.4,17–19 Such cardiac adaptations are
usually modest and fall within accepted normal limits. Occasionally,
however, athletes reveal marked electrical and structural expressions
that overlap with those observed in cardiac diseases.
It is imperative that clinicians adopt an individualized approach to
the interpretation of an athlete’s evaluation, as expression of the ath-
lete’s heart is influenced by several factors (Figure 1). Body size has an
important influence on cardiac dimensions, accounting for about 50%
of the variability of LV cavity size and mass in highly trained ath-
letes.4,20 Therefore, when assessing the extent of cardiac remodel-
ling, the absolute LV dimensions in an athlete should be viewed in the
context of the body size.4 Despite these observations, indexing the
structural and functional parameters is still limited in the clinical prac-
tice. The limitations of current scaling methods is underscored by the
fact that the most widely used method for calculation of the body
surface area (BSA; the Dubois regression) is an empirically derived
formula that was developed from nine cadaveric subjects and prone
to significant errors. Contemporary studies have suggested the use of
fat free mass, or (if impractical) the use of height for normalization of
cardiovascular variables.21
Women who regularly engage in sports show similar cardiac adap-
tations compared with male counterparts but commonly to a lesser
extent, in term of absolute values. Female athletes exhibit modest
absolute increases in LV wall thickness and cavity size, as well as mod-
est increases of right ventricular (RV) and bi-atrial cavity size when
compared with sedentary women.4,19,22,23
Ethnicity has emerged as a major determinant of cardiac adaptation
to exercise, with black athletes exhibiting a higher prevalence of elec-
trocardiographic anomalies and significantly more LV hypertrophy in
response to exercise training.17,23–25 Electrocardiographic anomalies
are present in up to 40% of black athletes with T-wave inversions
being present in a fifth of the cohort.26 Papadakis et al.17 demonstrated
that 13% of black athletes exhibit anterior T-wave inversion (V1–V4),
which when associated with ST-segment elevation is likely to repre-
sent a feature of the ‘black athlete’s heart’. In addition, 12% black ath-
letes exhibit a wall thickness >12 mm compared with only 2% of white
athletes.17 The challenge of differentiating between physiological LV
Athlete’s heart
Sporting 
discipline
Ethnicity
Body size
Gender
Age
Drugs
Cardio-
myopathy
Figure 1 Figure depicts the main physiological (blue) and patho-
logical (red) determinants that influence cardiac adaptations to
exercise training in athletes.
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hypertrophy and HCM in black athletes is further complicated by the
fact that they exhibit similar LV cavity sizes to white athletes and a
higher wall thickness to cavity ratio. Preliminary data from Arabic and
Asian athletes suggest a similar or even lower prevalence of LV hyper-
trophy than in white athletes27,28 (Figure 2).
With regard to age, some differences have been reported in senior
compared with younger athletes; master athletes show lower LV vol-
umes and mass compared with the younger counterpart by both
echocardiography and CMR, even though both these parameters are
still higher compared with age-matched untrained controls.29–31
Systolic function, in terms ejection fraction and two-dimensional (2D)
echocardiography strain imaging is usually preserved in master athletes
and not different from younger ones; conversely, with aging, changes
in diastolic function have been reported in master athletes with
smaller E and e0 waves and higher A and a0 waves.30 These changes in
diastolic function reflect the normal aging process of the left ventricle
and are similar to what occurs in untrained individual, therefore, it has
accepted that exercise activity, while providing prolonged diastolic
time associated with lower heart rate, however does not reduce the
impairment of early diastolic filling induced by age.32,33
2.2 Impact of type of sport on
cardiovascular adaptations
Cardiac adaptations in athletes mainly depend upon the characteris-
tics, intensity, and cumulative duration of training protocols, with a
‘dose-effect’ relation. Usually, in professional athletes, training sched-
ules involve >10–15 h/week of intensive exercise conditioning. In
detail, isotonic (dynamic) exercise is associated with a substantial
increase in cardiac output and reduction in peripheral vascular resist-
ance; therefore, endurance training mainly results in volume over-
load; conversely, isometric (static) exercise is characterized by less
increase in cardiac output and by a transient increase in peripheral
resistances; therefore, it training is characterized by a pressure over-
load.2,34–36 The first observation describing differences in cardiac
adaptations in relation to the type of sport was reported in 1975 by
Morganroth, who observed a concentric LV hypertrophy in isometric
sports and an eccentric LV hypertrophy in isotonic disciplines.36 This
hypothesis was subsequently expanded after 40 years of investiga-
tions and a vast literature has been assembled so far on the athlete’s
heart, including more recent studies with 3D echocardiography and
CMR.20,37,38 Most sports disciplines are characterized by a varying
degree of both isometric and isotonic components, and therefore
the original dichotomic classification in strength (isometric) or endur-
ance (isotonic) disciplines is not applicable for most athletes.
Therefore, we suggest a simple classification of sports in four major
groups based on the main physiologic characteristics of the exercise
training: endurance, power, skill, and mixed (Figure 3). Pelliccia et al.1
demonstrated that the highest impact on LV mass (with both
enlarged LV cavity and increased wall thickness) is associated with
some endurance disciplines such as cycling, rowing, swimming, and
cross-country skiing, that are all characterized by a high degree of
both dynamic and static components. In these athletes the substantial
degree of cardiac remodelling shows a close relation to the superior
exercise performance (as expressed by maximal oxygen consump-
tion).39,40 On the other side, predominantly strength disciplines are char-
acterized by only a mild absolute increase in LV wall thickness, which
only rarely exceeds the upper range of normalcy.41 Consequently, LV
mass is only mildly increased but, when normalized to athlete’s lean
body mass, may not be altered.41–45 This is justified by the fact that
strength training consists in short bursts of intensive exercise and pres-
sure overload, but of relatively short cumulative duration. In addition,
there are certain disciplines in which the success is mostly based on ath-
lete’s technical or bodily skill (skill disciplines) that have only mild cardio-
vascular demand and characterized by only mild or even absent cardiac
adaptations (no significant changes of LV dimensions and mass). Finally,
mixed sports are those with alternate phases of work (either dynamic
or static exercise) and recovery. Typical examples are the ball and
team activities. In such athletes, the cardiac remodelling shows increase
in LV cavity and modest change in LV wall thickness and LV mass.
Recently, Caselli et al.20 demonstrated that regardless of the type of
sport participated, the ratio between LV mass and end-diastolic vol-
ume remains constant, reflecting the balanced and harmonic remodel-
ling of physiologic LV hypertrophy in most sport disciplines. In clinical
practice, the relative wall thickness (calculated as twice the left ventric-
ular posterior wall thickness divided by LV diastolic diameter) may be
used to characterize the morphologic remodelling of the left ventricle,
with values between 0.30 and 0.45 compatible with physiologic remod-
elling.46 Similar adaptations also occur in the other cardiac chambers.
The haemodynamic overload caused by endurance training is also
responsible for the observed increase in left and right atrial volume and
right ventricular size. On the contrary, strength training does not seem
to change left atrial (LA) or right ventricular size substantially.19,47–49
In addition, other data suggest that endurance disciplines are also asso-
ciated with a significant but mild increase in aortic root dimensions,
while power disciplines have only a trivial impact.50 A practical conse-
quence of these observations is that the heart of an athlete is always
characterized by a harmonic and consistent increase in the dimension
of all cardiac chambers, while a non-harmonic (disproportionate)
remodelling potentially suggests a non-physiologic process.
Finally, in the presence of unusual or disproportionate cardiac
remodelling in relation to the sport participated and described phys-
iologic determinants, the potential impact of doping substances
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Figure 2 Ethnic-related differences of left ventricular hypertro-
phy in athletes. The bars represent the percentage of athletes show-
ing left ventricular wall thickness >12 mm on echocardiography in
Black, Caucasian, Asian and Arabic ethnicities, respectively.
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(mostly anabolic androgenic hormones, peptide hormones, growth
factors, erythropoietin or its derived, and stimulants) should always
be considered.8,42,43,51–53 A list of banned drugs is reported and
annually updated by the World Anti-Doping Agency. However, in
this setting, scientific evidence is lacking (because of the concealed
use of the drugs and obvious clinical and ethical limitations to per-
form a controlled study) and only inconsistent and circumstantial
observations have been reported so far. Most of the informations are
limited to anabolic androgenic hormones. Few studies demonstrated
that power athletes using these hormones typically show concentric
LV hypertrophy compared with non-user athletes.42,43,53–55
Specifically, anabolic androgenic steroids stimulate cellular protein
synthesis and promote the growth of all organs, including the heart;
cardiac effects can include the development of concentric hypertro-
phy and myocardial fibrosis which can persist after deconditioning
and years after discontinuation of drug abuse.51,56 On cardiac imaging,
concentric hypertrophy and impaired systolic and diastolic LV func-
tion, which are typically not present in non-user athletes, are suspi-
cious for drug abuse.54,55 Anabolic androgenic hormones users have
shown a higher mortality compared with clean athletes and postmor-
tem studies confirmed the existence of a drug-induced cardiomyop-
athy, characterized by greater cardiac mass, increased left ventricular
wall thickness, and a large prevalence of extracellular fibrosis.51,57,58
3. Indications for imaging testing
and normal findings in athletes
3.1 Clinical and electrocardiogram
abnormalities requiring cardiac imaging
Cardiovascular imaging usually represents an advanced step of
athlete’s evaluation and is preceded by physical examination and/or
12-leads ECG. Table 1 shows the most important clinical indications
to perform cardiovascular imaging in athletes. The ability to make
diagnosis of an abnormal cardiovascular condition in athletes mainly
depends on the clear understanding of the clinical context, on the
knowledge of the physiologic limits of cardiac adaptations, and on
being able to seek those conditions that are at potential risk for car-
diac arrest/sudden death (SCD) or adverse cardiac outcome. Most of
the cardiovascular diseases observed in athletes may be suspected on
the basis of an abnormal ECG (with the remarkable exception of cor-
onary artery disease (CAD)/anomalies and valvular heart disease).
Thanks to the large amount of data collected over the last decade,
our understanding and interpretation of the athlete’s ECG has
evolved and contemporary criteria have reduced the false positives,
improving the diagnostic efficacy. Specifically, after the initial work by
Corrado et al. in 2010, new refined criteria for ECG interpretation
have been subsequently published.16,26,59,60 These refined criteria
demonstrated to improve specificity up to 84% in black athletes and
94% in white athletes, without compromising the sensitivity of ECG
in detecting major cardiac pathologies (100%).26
According to contemporary recommendations for interpretation
of the athlete’s ECG, the ECG abnormalities are divided in three
groups according to their prevalence, relation to exercise training,
association with an increased cardiovascular risk, and need for further
clinical investigation to confirm (or exclude) presence of underlying
cardiovascular disease.59 The athlete’s heart is commonly (up to
80%) associated with ECG changes such as sinus bradycardia, first-
degree AV block, and early repolarization resulting from physiologic
adaptation of the cardiac autonomic nervous system to training, i.e.
increased vagal tone and/or reduced sympathetic activity. Moreover,
the ECG of trained athletes often exhibits pure voltage criteria for LV
hypertrophy that reflect the physiological LV remodelling, consisting
of increased LV wall thickness and chamber size. Although these
Sport Disciplines
Skill Power Mixed Endurance
Isometric +/-
Isotonic +/-
Cardiac remodeling +/-
• Golf
• Archery
• Sailing
• Table Tennis
• Equestrian
• Karate
• Shoong/Riﬂe
• Curling
• Sled disciplines
• Ski Jumping
• Weightliing
• Wrestling / Judo
• Boxing
• Short distance running
• Shot-pung
• Discus / Javelin
• Arsc gymnascs
• Bobsleigh
• Short-track skang
• Alpine skiing
• Snowboarding
• Soccer
• Basketball
• Volleyball
• Waterpolo
• Badminton
• Tennis
• Fencing
• Handball
• Rugby
• Hockey / Ice-hockey
• Cycling
• Rowing
• Mid/long distance swimming
• Mid/long distance running
• Canoeing
• Triathlon
• Pentathlon
• X-country skiing
• Biathlon
• Long distance skang
Isometric +++/++++
Isotonic +/++
Cardiac remodeling +/++
Isometric ++/+++
Isotonic ++/+++
Cardiac remodeling ++/+++
Isometric ++/+++
Isotonic +++/++++
Cardiac remodeling ++++
Figure 3 Simplified classification of the most common Olympic sport disciplines, according to the relative isometric and isotonic components of
exercise and resulting cardiovascular adaptation.
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Table 1 Clinical indications to perform cardiovascular imaging studies in athletes
Clinical history: Imaging tests
of choice
Heart disease Additional testing
SCD in the family Echocardiography Cardiomyopathies Clinical and genetic family screening in selected cases
Known cardiomyopathy
in the family
CMR Mitral valve prolapse
Palpitations Echocardiography Cardiomyopathies Consider 24-h and/or long-term ambulatory ECG
monitoring and/or electrophysiological study in selected cases
Syncope CMR Coronary artery disease/
anomalies
CT according to clinical suspicion
Consider stress echo to rule out LV outflow obstruction
Chest pain Echocardiography Coronary artery disease/
anomalies
Consider the risk profile, age and radiation exposure
CMR Consider exercise stress imaging
CT
Nuclear imaging
Physical examination Imaging tests
of choice
Heart disease Additional testing
Cardiac murmurs Echocardiography Valvular heart disease Additional tests on the basis of echocardiographic
findings and clinical suspicion (e.g. CMR)Abnormal cardiac sound Congenital heart defects
Marfanoid habitus Echocardiography Marfan disease Clinical and genetic family screening
CT Accurate evaluation of thoracic aorta
CMR
12-leads electrocardiogram Imaging tests
of choice
Heart disease Additional testing
T-wave inversion Echocardiogram Cardiomyopathies Clinical and genetic family screening
CMR Myocarditis Annual follow-up with imaging tests in athletes with
normal findings at initial evaluation
ST-segment depression Echocardiogram Cardiomyopathies Consider exercise stress imaging
CMR Myocarditis Coronary CT or nuclear imaging in athletes with
clinical suspicion of coronary artery diseaseCoronary artery disease
Valve disease
Pathologic Q-waves Echocardiogram Cardiomyopathies Consider exercise stress imaging
CMR Myocarditis Coronary CT or nuclear imaging in athletes with
clinical suspicion of coronary artery diseaseCoronary artery disease
Complete LBBB Echocardiogram Cardiomyopathies Comprehensive cardiac evaluation for exclusion
CMR Myocarditis of heart disease
CT Cardiac sarcoidosis Consider exercise stress imaging
Nuclear imaging Valve disease
Coronary artery disease/
anomalies
Bifascicular block (RBBB and left
anterior hemiblock)
Echocardiogram Cardiomyopathies Additional tests on the basis of echocardiographic
findings and clinical suspicionMyocarditis
Cardiac sarcoidosis
Coronary artery disease
Non-specific intraventricular
conduction delay
Echocardiogram Cardiomyopathies Additional tests on the basis of echocardiographic
findings and clinical suspicionCoronary artery disease/
anomalies
Minor non-voltage criteria for LV or
RV hypertrophy (atrial enlargement
and QRS axis deviation)
Echocardiogram Cardiomyopathies Additional tests on the basis of echocardiographic
findings and clinical suspicionValve disease
Congenital heart disease
Pulmonary hypertension
Abnormal exercise testing
(repolarization abnormalities/
symptoms/arrhythmias)
Echocardiography Coronary artery disease/
anomalies
Consider the cardiovascular risk profile and age
CMR Consider also exercise stress imaging
CT Cardiomyopathies Low-radiation examinations advised in young individuals
Nuclear imaging Myocarditis
CMR, cardiac magnetic resonance; CT, computed tomography; LBBB, left bundle branch block; LV, left ventricle; RBBB, right bundle branch block; RV, right ventricle; SCD, sud-
den cardiac death.
Cardiovascular imaging in athletes: EAPC/EACVI joint position statement 1953
D
ow
nloaded from
 https://academ
ic.oup.com
/eurheartj/article-abstract/39/21/1949/4210363 by U
niversity of Zurich user on 27 February 2019
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
..
.
ECG changes (i.e. training related) may be considered ‘abnormal’,
they do not imply the presence of cardiovascular disorders or an
increased cardiovascular risk in the athlete. These ECG abnormalities
should be clearly separated from training unrelated ECG patterns
(present in <5%), such as ST-segment depression and T-wave inver-
sion, pathologic Q waves, major intraventricular conduction defects,
ventricular pre-excitation, long or short QT interval, and ventricular
arrhythmias, which may be an expression of cardiovascular disorders,
notably cardiomyopathies and cardiac ion channel diseases, with
potential risk of SCD during sports.
Finally some borderline ECG variants (left and right atrial enlarge-
ment, left and right axis deviation, and right ventricular hypertrophy)
are considered of uncertain significance in athletes and, in the setting
of cardiac evaluation, should not require additional investigation if
not associated with positive family history and present in isolation.26
The ECG should be evaluated in relation with the athlete’s gender,
age and race, family history of cardiovascular disease and/or SCD,
clinical symptoms, physical examination, and intensity/duration of
physical exercise. In asymptomatic athletes with a negative family his-
tory, ECG changes due to cardiac adaptation to physical exertion
should not cause alarm and do not represent indication for additional
evaluation. Further diagnostic work-up, instead, should be reserved
to the limited subset of athletes with ECG changes potentially reflect-
ing underlying heart disease.
Genotype–phenotype correlation studies in cardiomyopathies
reveal that ECG abnormalities may represent the only sign of disease
expression in mutation carriers in the absence of any morphologic
typical features and even before structural changes in the heart may
become evident. Abnormal ECG repolarization in young and appa-
rently healthy athletes may represent initial expression of underlying
cardiomyopathy that may not be evident until many years later and
that may ultimately be associated with adverse outcomes. The obser-
vation that T-wave inversion may identify subjects at risk of subse-
quent development of structural heart disease underscores the
importance of continued clinical surveillance and follow-up. We sug-
gest that athletes with repolarization abnormalities, even in the
absence of structural heart disease at first evaluation (after compre-
hensive and multi-modality imaging), should have imaging studies on a
regular basis; usually echocardiography is sufficient on annual basis
but when images are suboptimal, other imaging modalities should be
considered.61
3.2 Echocardiography
Standard echocardiography helps to define the upper limits of ath-
lete’s LV hypertrophy. In a reference study of 1309 athletes, 55% had
an increased LV end-diastolic diameter and, of interest 14% had an
LV end-diastolic diameter >60 mm (mostly endurance athletes) in
the presence of normal ejection fraction (EF) and normal or
increased stroke volume (Table 2). Left ventricular size should there-
fore be considered in the context of exercise capacity, given its
robust association with VO2 max.
1,40 Left ventricular cavity is also
strongly related to body size, therefore scaling measurements to BSA
is advised in the clinical practice (upper limits in athletes have been
reported as: <35 mm/m2 in male and 40 mm/m2 in female).4
Maximal LV wall thickness is <12 mm in the majority of Caucasian
athletes, with only 2% ranging from 13 to 16 mm, and none >16 mm.1,62
Septal wall thickness is thinner in women (average = 9 mm, upper
limit = 11 mm) than in men of the same age and body size.63 Conversely,
in black athletes LV hypertrophy (LV wall thickness >_13 mm) is detected
in 18% of males and (LV wall thickness > 11 mm) in 3% of females23,64
(Table 2; Figure 2).
In adolescent athletes, LV end-diastolic diameter and LV wall thick-
ness exceed values of age- and sex-matched sedentary controls, but
are lower than those of adult athletes (LV end-diastolic diameter
<60 mm; LV wall thickness <11 mm).65
Most of the adaptations induced by physical training seem to
regress after temporary training suspension (deconditioning) of only
few weeks (9–12), while LV dilatation persists in 20% of the cases,
even after an average of 5 years of inactivity, without eliciting adverse
cardiovascular events during the follow-up.66
Left ventricular ejection fraction is usually unchanged in athletes.
Several studies and a meta-analysis confirmed that LV function in ath-
letes is not different from untrained subjects and EF is consistently
50%; therefore, the finding of a reduced EF (<50%) cannot be consid-
ered uniquely as a benign consequence of athletic training and
deserves careful clinical investigation.20,67
With regard to diastolic function, transmitral pulse wave Doppler
inflow pattern demonstrates a normal pattern, with an increased con-
tribution of early filling velocity at rest (E/A ratio >2)68,69 (Figure 4).
Pulsed tissue Doppler imaging (TDI) provides additional information
showing normal s0 peak velocity at rest (>8 cm/s) and e0 peak velocity
of the mitral annulus (>10 cm/s).68,70,71 Conversely, individuals with
mild morphological expression of HCM exhibit lower e0 velocity
compared with athletes.5 The full spectrum of systolic and diastolic
myocardial velocities has been described in large populations of com-
petitive athletes.68,72
Left atrial enlargement is common in large cohorts of athletes, pro-
portional to biventricular enlargement and affected by the type of
training. Pelliccia et al.19 reported a mild increase of LA diameter
(>_40 mm) in 18% and a marked LA dilatation (>_45 mm) in 2% of the
athletes. Left atrial volume is the preferred method for the assess-
ment of LA remodelling and D’Andrea et al. confirmed a mild enlarge-
ment by using LA volume index (LAVi >_ 34 mL/m2) in 24% and
moderate enlargement in 3% of athletes.48,73
Elite athletes have normal aortic root diameter measured at the
sinus of Valsalva and aortic valve annulus, with <1% of athletes showing
increased dimensions. Clinicians evaluating athletes should therefore
know that marked aortic root dilatation represents a pathological
process and not a physiological adaptation to exercise.50,74,75
Right atrium and right ventricle (RV) also undergo structural and
functional remodelling as a result of haemodynamic challenges of
exercise training.76 Endurance sport requires very high cardiac out-
puts to be sustained for long periods and, as a result, the right heart
undergoes substantial remodelling.29,47,76–78 A physiological RV
enlargement (usually proportional with LV enlargement) was
observed in both black and white athletes (Table 3).18 Despite signifi-
cant RV enlargement, athletes usually show normal RV systolic func-
tion, without significant differences compared with untrained
subjects.76,79 Only a small minority may present a mildly reduced RV
fractional area change76; ambiguities in the interpretation of mildly
reduced RV function may be resolved by assessing RV function during
exercise inducing both pressure and volume overload.80,81
Exercise stress echocardiography can be considered a very reliable
and non-invasive methodology to provide information on cardiac
1954 A. Pelliccia et al.
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function, contractile reserve, exercise capabilities, and arrhythmias,
which can be combined with clinical and ECG data and contribute to
detect cardiac abnormalities. Being a safe and well-tolerated test, it is
generally better accepted than pharmacological stress by individual
athletes.8,82 Typical indication of exercise echocardiography is the eval-
uation of global and regional cardiac function during exercise in cases
of suspect CAD or anomalies, in individuals with chest pain symptoms,
abnormal ECG or doubtful ECG stress test. In some elite endurance
athletes, both LV and RV dilatation has been reported to be associated
with a mild impairment of systolic function. In these cases, exercise
echocardiography enables the assessment of contractile reserve of the
dilated ventricles, with a significant improvement in contractility during
physical exertion, suggesting a physiological response.8,80,82 Finally, a
special mention deserve the evaluation of athletes with valvular heart
disease (i.e. haemodynamically significant valvular regurgitation, BAV,
and mitral valve prolapse); in these cases exercise echocardiography
may give complementary information on exercise tolerance, biventric-
ular contractile reserve, and changes of haemodynamic and valvular
functional parameters (such as valvular gradients, regurgitations, pul-
monary artery pressure, and diastolic function).82
3.3 Novel echocardiographic techniques
Speckle tracking (STE) and 3D echocardiography are not part of the
routine evaluation of the athlete, but may become useful in specific cir-
cumstances to clarify the nature of cardiovascular adaptations. The
indications to complete a routine echocardiographic examination in an
athlete with these advanced technologies are summarized in Table 4.
Left ventricular global longitudinal strain (GLS) obtained by STE is
currently the most used parameter in clinical practice. Main echocar-
diographic studies using 2 STE in the athlete’s heart are summarized
in Table 5. These studies demonstrate that a reduction in LV GLS is
an uncommon feature in athlete’s heart and cannot be considered a
physiological adaptation to training. The current normal value for
the general population varied from -16% to -22%, mean -20%.83,84
Similar values have been found in athletes, suggesting that a measure
<15% should raise the suspicion of an underlying myocardial disease,
particularly in case of other concomitant subclinical anomalies
(Figure 5).83–89
Speckle tracking echocardiography has been recently applied to
the investigation of the RV in athletes, providing new insights into the
mechanisms of its physiologic remodelling and the assessment of the
....................................................................................................................................................................................................................
Table 2 Athlete’s left heart morphologic and functional parameters including upper or lower limits
First author Year No. of athletes Type of sport Parameter Gender Mean value Cut-off value
Pelliccia 1999 1309 S P M E LV End diastolic diameter (mm) # 55 70
Whyte 2004 442 P E LV End diastolic diameter (mm) $ 49 65
Pelliccia 1996 600 S P M E LV End diastolic diameter (mm) $ 49 66
Makan 2005 900 E LV End diastolic diameter (mm) # and $ Adolescent 51 60
Spirito 1994 947 S P M E LV wall thickness (mm) # 10 16
Rawlins 2010 440 P E LV wall thickness (mm) $ Black 9.5 13
Sharma 2002 720 P E LV wall thickness (adolescent) (mm) # and $ Adolescent 9.5 12
Basavarajaiah 2008 300 P E LV wall thickness (black athletes) (mm) # Black 11.5 16
Caselli 2015 1145 S P M E LV mass/BSA (g/m2) # and $ 103 146
Finocchiaro 2016 1083 P M E LV mass/BSA (g/m2) # 83 117
$ 101 143
Pelliccia 2005 1777 S P M E LA antero-posterior diameter (mm) # 37 50
$ 32 45
D’Andrea 2010 650 P E LA volume index (mL/m2) # 28 36
$ 26.5 33
Pelliccia 2010 2317 P E Aortic toot diameter (mm) # 32 40
$ 28 34
D’Andrea 2010 615 P E Proximal ascending aorta (mm) # and $ 28 34
Caselli 2015 1145 S P M E LV ejection fraction (%) # and $ 64 55
E/A 1.93 1.3
TDI e0 septal (cm/s) 13.8 10.3
TDI e0/a0 septal (cm/s) 2.04 1.23
E/e0 septal 6.4 8.5
D’Andrea 2010 650 P E TDI s0 septal (cm/s) # and $ 13 8
TDI e0 septal (cm/s) 24 10
TDI s0 lateral (cm/s) 15 9
TDI e0 lateral (cm/s) 16 11
TDI e0/a0 lateral 1.45 1.2
D’Andrea 2006 155 P LV Intra-ventricular delay (ms) # and $ 9.5 45
BSA, body surface area; LA, left atrium; LV, left ventricle; TDI, tissue Doppler imaging. Type of sport: S, skill; P, power; M, mixed; E, endurance. $, female; #, male.
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..possible detrimental effects of strenuous and chronic exercise train-
ing on RV function, particularly in endurance athletes.33,49,90–96 Strain
and strain rate imaging, being able to objectively quantify regional RV
dysfunction, have demonstrated to improve the ability to diagnose
AC and to distinguish between physiology and pathology.33,97,98
However, studies investigating RV function in athletes by STE remain
limited and there is lack of universally accepted cut-off values
(Table 5).
Three-dimensional echocardiography has added quantitative infor-
mation on the assessment of the athlete’s heart, indeed cardiac vol-
umes and mass can be estimated more precisely without the use of
geometric assumptions and with very fast acquisition times.99–101
Three-dimensional derived information on LV geometry are very
close to those obtained by CMR while 2D echocardiography rou-
tinely underestimates these measurements.99,102 The geometric pat-
tern of LV adaptation to different training protocols have been
investigated with 3D echocardiography. In athletes, regardless to the
sport discipline, a balanced ratio between LV mass and end-diastolic
volume has been described by 3D echocardiography as opposed to
what typically occurs in cardiomyopathies.20,102,103 Additionally, the
distribution of hypertrophy within the LV has been further investi-
gated by the mass dispersion index (MDI; the standard deviation of
segmental LV mass) which is able to differentiate the homogeneous
segmental distribution of LV mass typical of athletes or hypertensive
patients compared with the non-homogeneous hypertrophy which is
usually expression of HCM.104
3.4 Cardiac magnetic resonance
Due to its diagnostic versatility, CMR imaging represents the second
most valuable imaging method in the routine screening of active ath-
letes and has definitely a role in the assessment of suspected cardiac
disease. Studies reporting the systematic use of CMR as screening
tool for cardiac abnormalities in athletes are, so far, scant and none
have reported malignant arrhythmias or SCD as outcomes related to
CMR findings.105–107 Additionally, it is worthy to consider that CMR
shows systematically larger atrial and ventricular dimensions and vol-
umes, and smaller wall thickness and mass, compared with echocar-
diography.108 Therefore it should be advised to use some caution in
applying echocardiographic derived reference values when perform-
ing CMR in athletes.
The main diagnoses relevant for a CMR study are: HCM, DCM,
AC, LVNC, BAV, aortic root diseases, myocarditis, pericarditis, and
ischaemic heart disease (see specific paragraphs). Figure 6 describes
the main patterns of relevant diseases associated with risk of SCD in
Figure 4 Twenty-two years-old male competitive endurance athlete (swimmer). Panel A: Apical 4-chamber and (Panel B) parasternal short-axis
views, showing left ventricular (LV) hypertrophy, with symmetric increase of both wall thickness and LV internal cavity diameters. Panel C: Standard
Doppler transmitral inflow pattern, showing a ‘supranormal’ early-diastolic function, with increased E velocity and E/A ratio. Panel D: Pulsed Tissue
Doppler pattern of LV lateral wall, highlighting the enhanced early-diastolic myocardial function, i.e. increased e’ velocity. LA, left atrium; LV, left ven-
tricle; RA, right atrium; RV, right ventricle.
1956 A. Pelliccia et al.
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..athletes in a stepwise selection decisional algorithm using CMR find-
ings after the whole patient’s data (including symptoms, personal and
familial history, electrocardiography, and echocardiography) have
been interrogated.
Protocols include multiplanar cine CMR to assess morphology and
function of all valves, especially the aortic valve and root whose
anomalies can lead to SCD. Most importantly, cine CMR evaluates
heart chambers volume and mass accurately and with high
reproducibility, and is considered the standard of reference for the
assessment of global and regional contractile function.39,109,110
Assessment of the RV volume, shape, and ejection fraction (EF)
are main CMR criteria recognized by the task force for imaging diag-
nosis of AC,111,112 although involvement of the LV may also occur.113
The dependence of the size of the RV to the gender and the BSA
highlights the need for indexing the RV parameters to the BSA.
Indeed, RV remodelling and enlargement are normal adaptations to
....................................................................................................................................................................................................................
Table 3 Athlete’s right heart morphologic and functional parameters including upper or lower limits
First author Year No. of athletes Type of sport Parameter Gender Mean value Cut-off value
D’Andrea 2013 650 P E RV diameter basal (mm) # 43.5 55
$ 39 49
RV diameter middle-ventricle (mm) # 34 47
$ 32 43
RV longitudinal diameter (base-to-apex; mm) # 89 109
$ 82 100
Zaidi 2013 675 P E RVOT proximal (mm) # 32 43
$ 30 40
RVOT distal mm # 23.5 32
$ 21.5 29
Zaidi 2013 675 E RA area (cm2/m2) # 19.5 28
$ 15.5 24
D’Andrea 2011 650 P E PASP (mmHg) # and $ 24 40
D’Andrea 2013 650 P E TAPSE (cm) # and $ 2.1 2.0
RV FAC (%) 48.5 47
Oxborough 2012 102 E RV TDI s0 (cm/s) # and $ 11 8
RV TDI e0 (cm/s) 10 6
D’Ascenzi 2016 1009 S P M E RVOT proximal (mm) # 28.4 34
RVOT proximal index (mm/m2) $ 26.1 32
# 14.4 18
$ 15.3 19
RVOT distal (mm) # 29.8 16
RVOT distal index (mm/m2) $ 27.3 34
# 15 19
$ 15.9 21
RV diameter basal (mm) # 40.6 49
$ 35.2 44
RV diameter middle ventricle (mm) # 27.3 35
$ 23.9 31
RV diastolic area (cm2) (male) # 25.1 33
$ 19.3 27
RV systolic area (cm2) (male) # 12.1 18
$ 9.0 14
TAPSE (mm) (male) # and $ 24 19
RA area (cm2) (male) # 18.9 25
$ 14.8 20
s0 (cm/s) # 14.8 12
$ 14.2 11
RV FAC (%) # 52.0 39
$ 53.4 38
FAC, fractional area change; RA, right atrium; PASP, pulmonary artery systolic pressure; RV, right ventricle; RVOT, right ventricular outflow tract; TDI, tissue Doppler imaging;
TAPSE, tricuspid anulus peak systolic excursion. Type of sport: S, skill; P, power; M, mixed; E, endurance. $, female; #, male.
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..training in amateurs and endurance athletes.114,115 Therefore, we
recommend that RV enlargement is defined only when end-diastolic
volume exceeds the major diagnostic criteria in the athletic popula-
tion (i.e. >_110 mL/m2 for male and >_100 mL/m2 for males).111 As the
systolic function of the RV is usually normal in athletes, both major
(RVEF <40%) and minor (RVEF < 45%) criteria should be considered
in the differential diagnosis.111
Assessment of LV hypertrophy or dilatation using cine CMR also
provides paramount diagnostic information. Diagnosis of HCM is
likely when myocardial hypertrophy has a focal distribution.116
Hypertrophic cardiomyopathy may nevertheless display a diffuse pat-
tern, difficult to differentiate from that occurring in certain hyperten-
sive individuals and normal athletes (especially Afro-Caribbean
males).24,62
Cardiac magnetic resonance is also considered as the superior
method for fibrosis imaging. The assessment of late gadolinium
enhancement (LGE) has excellent ability to outline myocardial
replacement fibrosis and is commonly used in detection of myocar-
dial scar and workup of cardiomyopathies,117–119 and differentiation
between diseased and adaptive athletes, even though small spots of
fibrosis have been occasionally reported in endurance athletes with-
out other obvious disease.120
Myocardial fibrosis can be characterized by typical ischaemic and
non-ischaemic patterns, with the latter including several subpatterns
with the potential to sharpen the differences between myocardial dis-
eases. For example, in diffuse LV hypertrophy, LGE helps distinguish-
ing potentially adaptive changes from diseases, among which the
most common is HCM (especially in the absence of LV overload)
Table 4 Indication to complete the routine echocardiographic evaluation by speckle-tracking or by 3D
echocardiography
Indications for speckle-tracking echocardiography
 Identification of pre-clinical anomalies useful to the differential diagnosis between athlete’s heart and early DCM (LV)
 Identification of pre-clinical anomalies useful to the differential diagnosis between athlete’s heart and early HCM (LV)
 Characterization of regional wall motion abnormalities (LV and RV)
Indications for 3D echocardiography
 Better assessment of LV volumes and function
 Assessment of pattern of LV geometry
 Quantification of the extent of LV trabeculation
DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; LV, left ventricle; RV, right ventricle.
....................................................................................................................................................................................................................
Table 5 Most relevant studies assessing left (upper panel) and right (lower panel) ventricular strain by speckle-track-
ing echocardiography in athletes
Author Year Sport discipline Nr Longitudinal strain
Left ventricle
Caselli et al. 2014 Olympic athletes 200 -18.1 ± 2.2%
Nottin et al. 2008 Elite cyclists 16 19.2 ± 1.9%
Cappelli et al. 2010 Endurance athletes 50 -18.4 ± 3.0%
Galderisi et al. 2010 Top level rowers 22 -22.2 ± 2.7%
Simsek et al. 2913 Marathon runners 22 -22.3 ± 2.2% (global)
Simsek et al. 2013 Wrestlers 24 -21.8 ± 1.7% (global)
Weiner et al. 2013 University Rowers 15 -16.8 ± 2.1% (pre-training)
-18.3 ± 2.8% (post-training)
Right ventricle
Teske et al. 2009 Endurance athletes/Olympic endurance athletes 58/63 -28.5 ± 2.9%/
-27.6 ± 3.1%
Oxborough et al. 2012 Endurance athletes 102 -27.0 ± 6.0%
Pagourelias et al. 2013 Endurance/Power athletes 80/28 -23.1 ± 3.7%/
-25.1 ± 3.2%
Esposito et al. 2014 Top level rowers 40 -26.3 ± 3.6% (global)
-29.1 ± 4.1% (free wall)
D’Ascenzi et al. 2015 Mixed sport disciplines 29 -28.7 ± 4.9% (Pre-season)
-29.2 ± 4.1% (Mid-season)
-30.0 ± 3.7% (End-season)
1958 A. Pelliccia et al.
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..where LGE is typically patchy or confluent and occurs at the RV
insertion.121–123 In normal-sized hearts, common non-ischaemic LGE
patterns involve the mid-wall and the subepicardium, figuring inflam-
matory disease-related necrosis or scars (myocarditis, sarcoidosis,
and collagen vascular diseases), while in dilated LV presence of LGE
suggests acute or subacute inflammatory diseases like DCM or pre-
dominant left-sided AC. Rare diseases should however, be consid-
ered in LV hypertrophy,124–128 and even other heart shapes when
the LGE pattern is atypical. Indeed, diffuse subendocardial, subepicar-
dial basal, and intramyocardial LGE have respectively been reported
in amyloidosis, Anderson-Fabry disease, and mitochondrial
myopathy.129,130
T1 mapping is a very promising CMR method for the assessment
of the extracellular volume and diffuse fibrosis. This technique can
potentially be important in myocardial diseases where LGE is less
sensitive.131 Indeed, the myocardial T1 values tend to increase with
the amount of extracellular matrix and aging,132 and decrease with
fatty infiltration such as in Anderson-Fabry disease.133,134
3.5 Computed tomography
Cardiac CT is characterized by a high-spatial resolution and short-
scan times, but limited temporal resolution, making the technique
ideal for high-resolution angiography. However before the indication
to CT scan, a due consideration concerns the radiation exposure135;
indeed, radiation dose of cardiac CT depends on the scanner type,
scan protocol, and the efforts taken to limit exposure. Dynamic eval-
uations using older scanners can result in doses exceeding 20 mSv,
while CT coronary angiography requires nowadays no more than 1
mSv in properly prepared patients using modern CT technology.136
Although many aspects of cardiac disease can be visualized well, car-
diac CT cannot be the first-choice imaging modality in young athletes.
Therefore, cardiac CT should be reserved for individuals with sus-
pected CAD (symptoms of angina, positive exercise test, arrhyth-
mias, or syncope during exercise), aortic diseases, or pericardial
pathology (Table 6). Cardiac CT is the most accurate technique for
imaging anomalous coronary anatomy, including intramural course.
The point of origin, course, adjacent structures, and termination (fis-
tulas) can be evaluated (Figure 7). However, morphology is often not
sufficient for interpretation of the pathophysiological relevance.
Obstructive coronary disease can be excluded in case of suspected
myocardial ischaemia.
Cardiac CT can also visualize most morphological features of the
different cardiomyopathies, including ventricular wall dimensions and
structure, cavity sizes, global contractile function, and even regional
wall motion abnormalities.137,138 However, although cardiac CT very
accurately measures global ventricular function, its practical use is
limited by the radiation exposure,139 hence, echocardiography and
CMR are preferred. In case of suboptimal echocardiographic images
and contraindications to CMR, CT scan may represent the alternative
imaging modality.
Figure 5 Left ventricular strain assessed by 2-dimensional speckle tracking echocardiography in a 20 year-old male soccer player. Global and
regional longitudinal deformation is assessed from apical 4-, 3- and 2-chamber views. Peak regional values are depicted in the bull’s eye plot in the
lower right panel. The global longitudinal strain (GLS) is -20% (in the range of normality).
Cardiovascular imaging in athletes: EAPC/EACVI joint position statement 1959
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Figure 6 Stepwise diagnostic algorithm involving Cardiac Magnetic Resonance (CMR) with inserts illustrating common diseases at risk for Sudden
Cardiac Death (SCD). CMR is usually performed as a second level cardiovascular examination. The first step examines cine images in order to dem-
onstrate/exclude aortic valve and root diseases (A and B are respectively end-diastolic transverse aortic and 3-chamber views displaying bicuspid
aortic (arrows) valve with regurgitation (arrowhead) and eccentric left ventricular (LV) hypertrophy, right ventricular (RV) dilatation and predomi-
nantly LV abnormalities. In case of RV dilatation, task force CMR criteria for the diagnosis of Arrythmogenic Cardiomyopathy (AC) should be
checked (J and K inserts are respectively end-diastolic and end-systolic short-axis cine views of a patient with recent onset of tachyarrhythmia, show-
ing enlarged RV (end-diastolic volume = 115 ml/m2) and dyskinetic segments in the inferior wall (arrows). The diagnosis of hypertrophic cardiomyop-
athy (HCM) is usually straightforward with focal LV hypertrophy (H and I inserts respectively represent end-diastolic and end-systolic 3-chamber
cine views, showing septal LV hypertrophy (asterisks). Late gadolinium enhancement (LGE) images are the next clue to the diagnosis in the remaining
cases (C-G inserts represent typical patterns of non-ischemic LGE on short-axis and 4-chamber views (arrowheads). These patterns are associated
to either disease-related focal myocardial damage or scar in normal-shaped LV, whereas they represent diffuse damage or end-stage cardiomyopa-
thies when the LV is dilated. When both cine CMR and LGE patterns are normal, coronary artery disease (CAD) can be excluded using Magnetic
Resonance Angiography (MRA) or stress CMR with respect to the patient age. AC, arrhythmogenic cardiomyopathy; CAD, coronary artery disease;
CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; LGE, late gadolinium enhancement; LV, left ventricle; MRA, magnetic reso-
nance angiography; N, No; RV, right ventricle; Y, Yes.
....................................................................................................................................................................................................................
Table 6 Indications to perform coronary computed tomography based on symptoms and age. Low-radiation examina-
tions advised in young individuals
Age category Suspect coronary artery disease Indication to perform CT coronary angiography
Young (<35 years) Coronary artery anomalies (origin, course) • Syncope
• Major ventricular arrhythmias induced by exercise
• Positive exercise test
Adults (>35 years) Atherosclerotic coronary artery disease • High risk profile
• Atypical chest pain
• Borderline exercise testing
CT, computed tomography.
1960 A. Pelliccia et al.
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Left-sided valve morphology can be assessed well, while CT imag-
ing of the right-sided valves is more challenging and requires specific
attention to contrast timing. Cardiac CT offers no flow-based func-
tional evaluation. Planimetry of stenotic valve areas has been
described.140 Pericardial thickening and calcification are well visual-
ized by cardiac CT, and pericardial fluid contents may to a degree be
differentiated by CT attenuation values. Finally, while cardiac CT may
be considered the clinical standard for aortic imaging, 3D CMR
angiography with or without contrast agent application is also of
high-diagnostic value and can easily be integrated in a single session
CMR examination.
3.6 Nuclear imaging
Both photon emission computed tomography (SPECT) or positron
emission tomography (PET) can be used in athletes for the assess-
ment of myocardial ischaemia when coronary artery anomalies or
disease are suspected, however ischaemia can also be related to
dysbalanced myocardial perfusion (e.g. in severe LV hypertrophy) or
microvascular disease. The technical details of these imaging modal-
ities have been described in the European guidelines for cardiac
nuclear imaging in 2008.141 In accordance with the ESC guidelines for
the management of stable CAD published in 2013, exercise ECG
should be the initial step in the diagnostic evaluation of athletes with
suspected CAD.142 Individuals with inconclusive exercise ECG
results could be referred for nuclear imaging. Similarly to CT, the
indication to perform nuclear imaging should be weighted to the risk
of radiation exposure.135 The effective radiation dose for myocardial
perfusion studies with novel scanners is <2 mSv for SPECT and <1
mSv for PET.143 The accuracy of both PET and SPECT to detect
CAD is very good, although PET may be preferred in balanced 3-ves-
sel disease since PET permits absolute quantification of myocardial
blood flow, representing the real added value of this technique,
whereas SPECT can only provide semi-quantitative values (normal-
ized to the maximum value), and can therefore not detect relative dif-
ferences in perfusion.144
4. Criteria for differential
diagnosis and risk stratification of
specific cardiac diseases
4.1 Hypertrophic cardiomyopathy
Hypertrophic cardiomyopathy is one of the most common causes of
SCD in young athletes and represents the basis for disqualification
from competitive sports according to both American and European
recommendations.3,9 The diagnosis relies on the presence of a hyper-
trophied LV (i.e. LV wall thickness >15 mm) in the absence of cardiac
or systemic disease capable of producing the same magnitude of LV
hypertrophy.145,146
The diagnosis of HCM in young competitive athletes may be chal-
lenging when the extent of LV hypertrophy is mild and LV wall thick-
ness is in the range of 13 mm to 16 mm, which identifies the ‘gray-
zone’ of overlap between the physiologic adaptations to training and
mild phenotypic expression of the disease.1,5,121,147
Cardiac imaging offers several clues for this differential diagnosis,
having in mind that no single parameter may ultimately be diagnostic
per se but final decision should always consider all clinical information
available (Table 7).
The most useful morphologic criterion is the assessment of LV
cavity size and geometry. Athletes in the gray zone typically show an
enlarged LV cavity (end-diastolic diameter > 54 mm), while HCM ath-
letes in the vast majority have a smaller cavity.5 Indeed, the shape of
LV chamber is altered in most HCM patients, due to the usual asym-
metric, segmental, and centripetal development of the pathologic
hypertrophy. However, in a few HCM athletes, especially those with
apical phenotype, the cavity size may exceed this limit.147 As a general
rule, the development of physiologic LV hypertrophy in the context
of the athlete’s heart is consistently associated with LV cavity enlarge-
ment with an eccentric pattern, at difference from HCM.20,103,104
The highest degree of LV hypertrophy in athletes is seen in male
gender, with values up to 15 mm in white and 16 mm in Afro-
American athletes.1,64 Less hypertrophy is found in female athletes,
with values up to 11 mm in whites and 13 mm in Afro-Americans.22,23
Figure 7 Cardiac Computed Tomography (CT) imaging of a
patient with non-compaction cardiomyopathy (B) as well as a single
coronary artery (A). LAD, left anterior descending artery; LCX, left
circumflex artery; RCA, right coronary artery.
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To be noticed that LV hypertrophy is typically found in sport with a
combination of high volume and pressure overload, such as rowing,
canoeing, and x-country skiing.1,20
Athletes usually show a homogeneous distribution of wall thick-
ness with absolute differences of <2 mm between the thickest and
the thinnest segments of the LV. On the contrary, an asymmetric and
heterogeneous pattern of LV hypertrophy represents a non-
physiologic condition, or phenotypic expression of HCM.5,104
Athletes show a preserved LV chamber geometry with mitral valve
normally located. Certain mitral abnormalities may be present in
HCM athletes, such as elongation of mitral chordae, with systolic
anterior motion and flow acceleration in the LV outflow tract, a phe-
nomenon that has not been described in athletes.148 Additionally,
while LV outflow obstruction may not be evident under resting con-
ditions, it could be precipitated by an exercise and demonstrated on
stress echocardiography in HCM patients.149
Left ventricular systolic function is usually within the range of nor-
mality in both athletes and HCM patients. Only subtle differences in
myocardial contraction can be detected by STE. Preliminary observa-
tions suggest that HCM with mild LV hypertrophy (12–16 mm) may
have a reduction in longitudinal endocardial strain, with cut-off value
<-15% able to identify pathologic hypertrophy with good accuracy
(sensitivity 79%; specificity 67%). Therefore, values below this cutoff
may be suggestive for pathologic LV hypertrophy.84,150
One of the most consistent features of the athlete’s heart is the
normal diastolic function, expression of preserved elastic, and recoil
LV properties.68,151 Conversely, in HCM patients LV diastolic func-
tion may present impairment as an expression of myocyte alteration
and interstitial fibrosis. Few individuals may show an inversion of the
E/A ratio, but most frequently in HCM a subclinical impairment is
associated with a reduction of the e0 velocity on TDI.5,147,151
Cardiac magnetic resonance is indicated when echocardiographic
images are not able to clearly identify all myocardial segments in
order to exclude focal areas of hypertrophy (such as the apex and lat-
eral wall). Indeed, CMR should be performed in all cases with associ-
ated marked ECG abnormalities and/or arrhythmias.152 The higher
contrast of CMR images between endocardial surface and the blood
pool allows a better definition and distribution of LV hypertrophy
and areas of focal hypertrophy. Most importantly, the use of LGE
enables tissue characterization and identification of focal areas of
myocardial fibrosis, commonly seen in patients with HCM.153
When the differential diagnosis remains still unresolved, useful
information may come from detraining, with serial imaging testing
(echocardiograms or CMR) after temporary interruption of training.
It has been demonstrated that after a short period of detraining (3-
month), regression of LV hypertrophy may be observed in athletes,
while this is unlikely to occur in HCM.66,154,155
It is worthy to mention that left atrial size may not be particularly
helpful in this specific scenario. Left atrial enlargement has been
described in athletes as an expression of global cardiac adaptation to
training and is typically associated with increased LV size, at difference
than in HCM where LV cavity is usually of normal size or even
reduced and LA appears disproportionately enlarged.19,48
Additionally, while in older HCM patients LA enlargement is a com-
mon finding and is considered a reliable criterion for the diagnosis
and risk stratification, in young and asymptomatic HCM patients with
mild expression of the disease, this finding may not be present as
well, with the apparent paradox that young athletes may have larger
LA compared with young HCM patients.5
4.2 Dilated cardiomyopathy
The sports activities most often associated with LV chamber dilata-
tion are those with high-isotonic/dynamic components, such as
cycling, cross-country skiing, canoeing, and rowing.1,4,20
Left ventricular cavity enlargement in athletes should always be
interpreted in the context of sport discipline participated and body
size (it is advised to relate LV cavity diameter to BSAs, as previously
reported) and is usually associated with increased wall
thickness.4,46,156 It has been reported that 38% of 950 elite athletes
engaged in different sports disciplines showed increased LV end-
diastolic diameter (>55 mm).1 In a very large population of elite ath-
letes, a substantial subset of 14% have a LV end-diastolic chamber
markedly enlarged, with LV diameter > 60 mm, with 99th percentile
corresponding to 65 mm.4 In a group of very elite professional cyclists
(n= 286) participating to the Tour de France, 45% had disproportion-
ate chamber dilatation (LV diameter > 60 mm) and a small minority
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 7 Cardiac imaging findings consistent with diagnosis of athlete’s heart when left ventricular wall thickness is
mildly increased, ranging from 13 mm to 16 mm
Diagnosis of athlete’s heart in the gray-zone of left ventricular hypertrophy(13–16 mm)
HCM Findings Athlete’s Heart
þ Family history of sudden cardiac death/HCM –
þ Major ECG abnormalities (ST segment/T wave inversion, wide, and deep Q waves) –
þ Normal or reduced LV cavity size (<54 mm) –
þ Abnormal LV cavity geometry and/or segmental LV hypertrophy –
þ LV outflow tract obstruction –
þ Abnormal LV diastolic relaxation/filling(septal e0 velocity < 8.0 cm/s and/or E/A ratio < 1.0) –
þ Left atrial remodelling disproportionate to LV remodelling –
þ Positive LGE on CMR –
þ Unchanged LV wall thickness after detraining –
CMR, cardiac magnetic resonance; HCM, hypertrophic cardiomyopathy; ECG, electrocardiogram; LGE, late gadolinium enhancement; LV, left ventricular.
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..also showed mildly impaired ejection fraction.157 However it has
been questioned whether these disproportionate cardiac adaptations
were the results of illicit drug abuse.51,157 Therefore, these findings
could theoretically be a challenge for distinguishing the physiologic
LV remodelling occurring in athletes from DCM.
It is worthy to notice that LV dilation in athletes is commonly
associated with normal systolic function (EF > 50%). A large study
involving more than 1000 Italian Olympic athletes of different
sport disciplines showed normal LV ejection fraction in the
entire study population, with lowest value being 53%, and fifth
percentile equal to 55% (Figure 8).68 Moreover, indices of dia-
stolic filling and relaxation (by Doppler-echocardiography and
TDI) are within normal limits.68 In case of mildly reduced ejec-
tion fraction (i.e. EF >_ 46%, <55%), it may be useful to assess LV
function during exercise (by echocardiography or radionuclide
imaging) (Figure 9). Absence of significant improvement of systolic
function at peak exercise (i.e. an increase in ejection fraction
<15% compared with the baseline value) is in favour of a patho-
logical dilatation. Moreover, in doubtful cases, the assessment of
peak oxygen uptake, which is consistently increased in relation
to total heart volume can also help us to distinguish between
physiologic and pathologic LV dilatation.158
Finally, STE might give additional information in terms of myo-
cardial contraction. However, only few studies are available to
date with somewhat diverse results on LV function at
rest.86,159,160 The results are, indeed, not strikingly different from
normal ranges. So far, no study has directly compared myocardial
strain in athletes and DCM.
Additional value is offered by the CMR with LGE. Cardiac
magnetic resonance provides accurate measurements of actual
dimensions and, in this context, the presence of positive LGE
could be expression of myocardial fibrosis more consistent with a
diagnosis of DCM.161 Importantly, the absence of LGE does not
exclude DCM.
4.3. Arrhythmogenic cardiomyopathy
Imaging criteria form an important part of the international diag-
nostic framework for arrhythmogenic cardiomyopathy (AC;
previously defined arrhythmogenic right ventricular
Figure 8 Left ventricular ejection fraction measured by echocardiography in a population of 1145 Olympic athletes (age 26 ± 5 years; 61% male),
free of cardiovascular disease, engaged in different sport disciplines. LV ejection fraction was normal in the entire study population with the lowest
value 53% and fifth percentile 55%. Data from Caselli S et al. Patterns of Left Ventricular Diastolic Funcrion in Olympic Athletes. J Am Soc Echocardiogr
2015;28:236–244.
Echocardiography
LV end diastolic 
diameter
>60 mm 
Reduced EF
Exercise test
Abnormal funcon
CMR
LGE+
DCM
Exercise test
Normal LV funcon
Athlete
>60mm
Normal EF 
Athlete
Figure 9 Proposed diagnostic algorithm for the differential diag-
nosis between physiological left ventricular cavity dilation in athletes
and dilated cardiomyopathy. CMR, cardiac magnetic resonance;
DCM, dilated cardiomyopathy; EF, ejection fraction; LGE, late gado-
linium enhancement; LV, left ventricle.
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cardiomyopathy/dysplasia, ARVC/D), as outlined in the modified
Task Force criteria proposed in 2010, and in the recent EACVI
recommendations.14,111 Electrical changes, which often form the
hallmark of the diagnosis of AC should be interpreted in the con-
text of the imaging findings: these include repolarization changes
in the right precordial leads (although not very specific)7,162; low
right precordial QRS amplitudes; epsilon waves; late potentials
(especially when 3 out of 3 criteria); frequent ventricular prema-
ture beats or non-sustained ventricular tachycardia from the RV
(especially when not from the RVOT)7,163; or inducibility during
EP study.164 Of relevance, it should be noted that electrical
changes in athletes could precede over long-time the morphologi-
cal changes in athletes with AC.61 Although 2D echocardiography
provides a readily available imaging tool, it has important limita-
tions for visualizing the complex geometry of the RV. Therefore,
modern imaging relies more on CMR.
Athlete’s hearts are by definition larger than untrained hearts.
Moreover, it is known that endurance exercise selectively promotes
RV dilatation due to the increase in RV wall stress during high cardiac
output conditions.76,164,165 Many endurance athletes have slightly
larger RV than LV volumes.165,166 Physiological RV remodelling is
characterized by consistent increase in RV inflow and outflow seg-
ments, at difference from the predominant increase of the outflow
tract observed in AC patients.167 The AC Task Force criteria pro-
posed defined dimensional criteria in the presence of regional wall
motion abnormalities.111 With regard to RV size, the criteria are
based on data derived from AC patients vs. normal controls, not
including healthy athletes, which represents a potential limitation.
Actually, up to 30% and 60% of athletes have RV dimensions that
would match respectively the ‘major’ and ‘minor’ Task Force crite-
ria.76,95 Right ventricular dilatation in athletes may be suggestive for
AC only when is really extreme.7,96,168 Therefore, we have proposed
that only major dimensional criteria, indexed by BSA should be used
to define RV enlargement in athletes: specifically, RVOT > 19 mm/m2
in long axis, and/or >21 mm/m2 in short axis, and/or RV end-diastolic
volume on CMR >_110 mL/m2 in males and >_100 mL/m2 in
females.7,76,163 Nevertheless, RV dimensions by themselves are insuf-
ficient criteria to distinguish physiologic from pathologic RV dilata-
tion, and need to be associated with regional wall motion
abnormalities.111 Other useful measures that have shown specificity
for AC include the ratio (on echocardiography) of RV inflow dimen-
sion (in the apical view)/LV end-diastolic dimension (parasternal
long-axis view) >0.9, or a ratio of RVEDV/LVEDV >1.2 on CMR.7
Functional measures are more important than pure dimensions.
Again, CMR may perform better than echocardiography. Regional
akinesia, dyskinesia, or aneurysmal deformation are important find-
ings, since they are present in more than half of AC patients. Also
measures of global dysfunction are useful: e.g. RV fractional area
change on echocardiography <33%, or RVEF <_40 on CMR.7,163 With
regard to STE, RV global longitudinal strain (RV-GLS) and strain rate
in athletes are comparable to non-athletes.95,96 On the contrary, AC
patients may show a subclinical RV dysfunction with reduced RV-
GLS, and further decrease is observed in those AC patients regularly
engaged in sport activities.169 Additionally, mechanical dispersion of
right ventricular contraction detected by STE may represent an early
predictor of future arrhythmic events.98,170 While LGE on CMR is
seen in >40% of familial forms of AC (due to desmosomal mutations),
it is still not part of the current AC Task Force criteria. Often LGE is
present also or exclusively in the LV, as it is recognized that LV
involvement of familial AC is common.
New data indicate that morphologic and functional evaluation of
the RV both with echocardiography and CMR during exercise (i.e.
not at rest) can be of help in the differential diagnosis of pathologic
RV remodelling.81,94,171 Indeed, athletes with subclinical AC may
have volumetric or functional values within normal range at rest,
while showing subnormal augmentation of RV systolic function dur-
ing exercise.80,94,163,172 Table 8 summarizes the most common crite-
ria that may help in differential diagnosis between physiologic RV
adaptation in athletes as opposed to AC.
4.4 Left ventricular non-compaction
Left ventricular non-compaction is a relatively novel cardiomyopathy
that is characterized by prominent myocardial trabeculations and
deep inter-trabecular recesses.173–176 Knowledge relating to the pre-
cise stage of development and the natural history of the disorder is
still incomplete, however available data are suggestive of a morpho-
logically and clinically heterogeneous disorder. Whereas some
individuals present with overt heart failure and potentially fatal
arrhythmias, others may remain asymptomatic.175 The clinical diagno-
sis is currently reliant on three proposed echocardiographic criteria
and are based on the demonstration of high non-compacted to com-
pacted ratio within the LV myocardium.173,174,177
Advances in tissue harmonics and image resolution in echocardiog-
raphy have coincided with increased reports of features consistent
with LVNC in patients with heart failure,176 as well as in low-risk
cohorts including sickle cell patients178 and athletes,179–184 particu-
larly those of African/Afro-Caribbean origin. A study of over a 1000
asymptomatic athletes demonstrated that 18% exhibited increased
LV trabeculations and 8% fulfilled echocardiographic criteria for
LVNC, more commonly in black athletes.179 A small proportion
(0.9%) of these athletes also exhibited concomitant T-wave inversion
and reduced indices of systolic function that may be considered diag-
nostic of LVNC, a finding that was also reported in Dutch football
players.180
At the moment is debated if these findings could be considered
incomplete expression of LVNC phenotype that may be unmasked
through intensive exercise training, or conversely, if they may repre-
sent just atypical features of cardiac adaptation. The precise mecha-
nism for the development of increased LV trabeculations in low-risk
cohorts is unclear, however, it has been observed that an increased
cardiac preload is the common factor in situations associated with
increased LV trabeculations, such as heart failure, chronic anaemia,
and athletic training. It is therefore possible that an increase in pre-
load may unmask a pre-existing trabeculation. The hypothesis is sup-
ported by a longitudinal study, using the pregnancy model to assess
the impact of a physiological increase in cardiac loading conditions on
LV trabeculations.185
A multimodal diagnostic approach is recommended for the diag-
nosis of LVNC in athletes.184 We propose the following guidance on
the assessment of athletes presenting with increased LV trabecula-
tions, here defined as showing a non-compacted to compacted (NC/
C) layer ratio >2.0 in systole on echocardiography or >2.3 in diastole
on CMR (Table 9).173,186 Cardiac symptoms or a family history of
heart failure, or premature SCD in an athlete fulfilling criteria for
1964 A. Pelliccia et al.
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LVNC favours cardiac pathology. Information from screening of first-
degree relatives for features of LVNC is invaluable but not always
practical. Additional echocardiography features of LVNC include low
ejection fraction that does not improve (by at least 20%) with moder-
ate exercise (70% of the maximum predicted heart rate), a mean e0 <
9 cm/s at echocardiography, and a thickness of compacted layer in
systole <8 mm.187 During maximal exercise testing, features favour-
ing LVNC include peak oxygen consumption less than predicted
value from healthy controls, or occurrence of complex ventricular
arrhythmias. Abnormal myocardial strain patterns are in the experi-
mental phase for this condition but an abnormal parameter may sug-
gest a disease process.188 Finally, detection of areas of LGE within the
LV on CMR is in favour of a cardiomyopathic process.189
4.5 Aortic root disease and bicuspid
aortic valve
Remodelling of the aortic root may be expected to occur in athletes
as a consequence of haemodynamic overload with exercise train-
ing.50,74,190–192 Technically, aortic root diameter measurements
should be made from the parasternal long-axis view using the leading
edge-to-leading edge convention and preferring 2D measurements
rather than M-mode measurements.73
Measurements ideally should include: (i) the aortic valve annulus
(hinge point of aortic leaflets), (ii) the sinuses of Valsalva, (iii) the sino-
tubular junction, and (iv) the proximal ascending aorta (Figure 10).73
Several observational studies performed in the general non-
athletic population reported that height and body size are the most
relevant determinants of aortic root size.75,193–195 Iskandar and
Thompson75 in a meta-analysis including a cohort of 5580 elite ath-
letes and 727 controls reported that athletes have greater aortic
root diameters compared with control subjects; however the effect
of exercise training on aortic size was small and most pronounced in
those engaged in endurance disciplines. Other studies on different
athletic populations reported a low prevalence of aortic enlargement
(>40 mm in males) in athletes.50,74,190,191,196 Pelliccia et al.50 in a large
cohort of 2317 elite athletes reported 1.3% of aortic root enlarge-
ment (17 males) with the 99 percentile equal to 40 mm in males and
34 mm in females. This value is recommended as cut-off for
evaluating aortic root diameters in elite athletes. In order to avoid
the confounding effects of body size and age, the American College
of Cardiology and the American Heart Association have recently
proposed the use of Z-scores to identify subjects with significant
aortic root dilation (i.e. Z-score > 2).11
In athletes with an aortic root dimension above the reference val-
ues, the presence of associated pathologic conditions including
Marfan Syndrome or BAV should be excluded.197,198 In athletes with
dilated aortic root, even in the absence of recognized structural sys-
temic/cardiac disease, a periodical clinical and diagnostic assessment
with non-invasive imaging should be recommended, to monitor
aortic root dimensions over time and recognize an accelerated
enlargement.
Bicuspid aortic valve is one of the most common congenital car-
diac anomalies, with prevalence between 0.5% and 2% in the general
population.199 In large athletes population the prevalence of BAV
has been reported as 1%.200 Inherited disease is described in up to
....................................................................................................................................................................................................................
....................................................................................................................................................................................................................
Table 8 Clinical and multi-modality imaging findings that may help in differential diagnosis between physiologic RV
adaptation as opposed to AC
Differential diagnosis between athlete’s heart and AC
AC Findings Athlete
þ Family history of sudden cardiac death/AC -
þ Anterior T wave inversion on ECG -
þ Ventricular arrhythmias with LBBB morphology -
þ Exercise induced VT -
þ RV size exceeding major Task Force Criteria for echocardiography or CMR (consider only indexed values) -
þ Regional wall motion abnormalities (akinesia or dyskinesia) on cardiac imaging. -
þ Global RV dysfunction on echocardiography (RVFAC < 33%) or CMR (RVEF <_ 40) -
þ Abnormal RV function on exercise echocardiography/CMR -
AC, arrhythmogenic cardiomyopathy; CMR, cardiac magnetic resonance; ECG, electrocardiogram; LGE, late gadolinium enhancement; LBBB, left bundle branch block; RV, right
ventricle; RVEF, right ventricular ejection fraction; RVFAC, right ventricular fractional area change; VT, ventricular tachycardia.
................................................................................................
.................................................................................................
Table 9 Findings consistent with diagnosis of athlete’s
heart or left ventricular non-compaction when
increased trabeculations are occasionally found on
echocardiography in athletes
Athletes with increased trabeculations
LVNC Findings Athlete
þ Family history of sudden cardiac death/LVNC -
þ Symptoms -
þ Reduced LV systolic function (EF < 50%) -
þ Reduced thickness of compact layer -
þ Late gadolinium enhancement on CMR -
þ T-wave inversion on ECG -
þ Left bundle branch block on ECG -
þ Exercise induced VT/AF -
þ Abnormal diastolic function -
AF, atrial fibrillation; CMR, cardiac magnetic resonance; ECG, electrocardiogram;
LV, left ventricle; LVNC, left ventricular non-compaction; VT, ventricular
tachycardia.
Cardiovascular imaging in athletes: EAPC/EACVI joint position statement 1965
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10–17% of first-degree relatives.201 As such, early detection of this
entity is of great importance, particularly due to the fact that in up to
30% various complications can interfere.202 Beside possible progres-
sion to valve dysfunction (stenosis or regurgitation), individuals with
BAV present with larger dimensions of the aortic sinus, ascending
aorta, and aortic arch compared with those with a tricuspid aortic
valve. They harbour an increased risk for progression and, in the very
worst case, aortic dissection.203,204 However, not all individuals with
BAV seem to be at risk for progressive aortic dilation, and thus it is
important to identify athletes at highest risk for aortic complica-
tions.200 This can only be achieved by regular echocardiographic
follow-up. Furthermore, BAV may be associated with additional dis-
eases (particularly in case of an autosomal-dominant inheritance pat-
tern). As such, coarctation of the aorta, interrupted aortic arch,
patent ductus arteriosus, coronary anomaly or hypoplastic left heart,
as well as Williams or Turner syndrome have to be excluded.205–207
Only a few studies have addressed the outcome of BAV in the gen-
eral population: in one study, 25% to 42% of subjects with BAV
required surgery for symptomatic valve disease, LV dysfunction,
ascending aortic dilation, or endocarditis.204,208 However, overall life
expectancy is not decreased in patients with BAV.204,209 A recent
international registry on BAV reported that the presence of raphe
was associated with higher prevalence of valvular dysfunction and
increased rates of surgery.210 Endocarditis may complicate BAV dis-
ease in about 10–30% during life, however, antibiotic prophylaxis is
currently not routinely recommended in isolated BAV.211
Outcome data on athletes are sparse but generally, adverse out-
come depends on various predictors (e.g. age > 30–50 years and
aortic dimension of >40 mm or, at least, moderate aortic valve dys-
function at baseline).200,204,212,213
Bicuspid aortic valve may be difficult to diagnose in athletes and
may sometimes be missed; careful physical examination may reveal a
mild murmur and/or a characteristic mid-systolic ‘click’.
Echocardiography is the imaging modality of choice when BAV is sus-
pected. The number of leaflets, leaflet fusion, and the presence of a
‘raphe’ can be reliably determined in the short-axis view, while
systolic doming and eccentric diastolic closure of the leaflets can be
visualized in the long-axis view. Two- or three-dimensional transoe-
sophageal echocardiography may further improve the accuracy for
diagnosis and correct assessment of BAV (Figure 11).214 Associated
coarctation of the aorta can be suspected on echocardiography but
needs to be confirmed by CT or CMR. Furthermore, Doppler echo-
cardiography allows accurate assessment of valve dysfunction.
Presence of valvular regurgitation or stenosis should be properly
assessed according to most recent guidelines.215,216 In case of valvular
regurgitation and LV cavity dilation, the latter should be interpreted
in the context of sport discipline participated and body size, using
normalized values as advised.4,12 Finally, it may be appropriate to
obtain an exact assessment of the ascending aortic diameters by an
additional CT or CMR scan at least as an index at ‘baseline’ and in
case of aneurysmatic aortic dilation with potential indication for
surgery.217
4.6 Mitral valve prolapse
Mitral valve prolapse (MVP) is the most common valvular disease in
the general population, with an estimated prevalence of 2–3%; it is
defined as an abnormal systolic displacement of one or both leaflets
into the left atrium below the mitral annulus, due to structural elon-
gation or abnormal distensibility of the mitral valve.218 The main
echocardiographic characteristic is the displacement of one or both
leaflets >2 mm beyond the annulus (from the parasternal long-axis
view) associated with maximal leaflet thickness >_5 mm (in the classic
MVP) or <5 mm (in the non-classic MVP).219–221 Although MVP is
generally regarded as a benign condition, the outcome is widely het-
erogeneous, and complications such as mitral regurgitation, atrial
fibrillation, congestive heart failure, endocarditis, ventricular arrhyth-
mias, and SCD have been reported.220,222,223 In detail, the estimated
rate of SCD in MVP ranges from 0.2%/year to 0.4%/year in prospec-
tive follow-up studies and recent evidence seems to suggest that
MVP is an underestimated cause of arrhythmic SCD, mostly in young
adult women.15,220,224 Most importantly MVP has been reported to
account for a large proportion (as high as 11%) of the overall causes
of SCD in young competitive athletes.225
Echocardiography is the imaging technique of choice for the diag-
nosis and characterization of MVP and is generally indicated when the
typical end-systolic murmur associated with mid-systolic click is iden-
tified on physical examination. The entity of leaflet prolapse, charac-
teristics and quantification of mitral regurgitation jet, LV size and
function, and left atrial size should be reported and periodically re-
evaluated. Mitral valve regurgitation should be assessed according to
most recent guidelines.215 In presence of LV cavity dilation, the spe-
cific impact of mitral regurgitation should be interpreted in context
of athlete’s type of sport participated and body size (specifically in
endurance athletes LV is considered dilated when end diastolic diam-
eter exceeds 35 mm/m2 in males and 40 mm/m2 in females).4,12 In
case of ventricular arrhythmias on resting or exercise ECG (especially
those with right bundle branch block morphology) a CMR should be
requested in order to exclude the presence of areas of fibrosis which
may be correlated with severe ventricular tachy-arrhythmias.15
4.7. Myocarditis
Myocarditis is an inflammatory disease of the heart muscle that occa-
sionally affects young individuals including athletes. The viral aetiology
Figure 10 Parasternal long-axis view of the aortic root and
ascending aorta in end-diastole in a 18 year-old male soccer player.
The measurements of aortic root at sinuses of Valsalva (A), sinotub-
ular junction (B), and proximal ascending aorta (C) are reported.
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..is largely predominant in developed countries.226,227 The clinical
course is variable ranging from mildly symptomatic to fulminant dis-
ease. Some patients heal completely with the elimination of patho-
gens and resolution of the inflammatory process, but in others, the
activation of autoimmunity may evolve in a chronic disease and/or
DCM.228,229 During all the phases of the disease, the interstitial
oedema, myocardial necrosis, and fibrosis represent the myocardial
substrate for the electrical instability.225,227,228 In this scenario, the
sport activity may trigger malignant arrhythmias which may ultimately
culminate in SCD.3,225
The clinical suspicion of myocarditis may rise from clinical history
of a recent respiratory or gastrointestinal tract infection. Patients
may report fever, chest pain, palpitation, and decreased physical per-
formance; laboratory testing may reveal increased inflammatory
markers (C-reactive protein and erythrocyte sedimentation rate)
associated with an otherwise unexplained rise in cardiac troponin.227
However, it should be noticed that clinical presentation might be
subtle and inflammatory markers only mildly elevated.
Electrocardiographic findings are not specific and include most
commonly repolarization abnormalities and atrial or ventricular
arrhythmias.3,226 Indeed, isolated or complex ventricular arrhythmias
during an exercise test may be one of the first manifestations of the
disease.
On echocardiography, the LV may be dilated with thin myocardial
walls resembling DCM, or non-dilated with increased myocardial
wall thickness due to myocardial oedema. Global systolic function
may be mildly reduced and, of relevance, focal regional wall motion
abnormalities may be observed. Concomitant pericardial effusion
may suggest pericardial involvement.227
Over the last decade CMR has acquired an increasingly role for
the diagnosis of myocarditis: an international consensus group
reported that, in the appropriate clinical context, the diagnosis of
myocarditis is defined by at least 2 of 3 of the following findings:
(i) regional or global myocardial signal intensity increase in T2-
weighted images; (ii) increased global myocardial early gadolinium
enhancement ratio between myocardium and skeletal muscle in
gadolinium enhanced T1-weighted images; (iii) at least one focal lesion
with non-ischaemic regional distribution in inversion recovery-
prepared gadolinium enhanced T1-weighted images.
230
Furthermore, the identification of LGE may confer prognostic
information, since it is a strong independent predictor of events dur-
ing follow-up.231–233
The clinical significance of persistent area of LGE in an asympto-
matic athlete with clinically healed myocarditis is still unresolved; it is
reasonable to assume that after clinical resolution of the diasese the
absence of symptoms, LV dysfunction, ECG abnormalities, and
arrhythmias on 24-h Holter ECG/exercise test represent a low-risk
condition and the athlete may resume training and competition under
strict clinical surveillance.
4.8 Congenital coronary artery anomalies
The estimated prevalence of congenital coronary artery anomalies
(CCAA) in the general population is quite variable, depending on
both the definition and the source of data, ranging from 0.21% to
5.79%. Despite the low prevalence, CCAA are well recognized as
major cause of SCD in competitive athletes, accounting for about
17% of such deaths in the USA and for 16% in Italy.
However, not all CCAA have the same prognostic impact, the
anomalies considered at risk of SCD on effort include an anomalous
origin from a wrong aortic sinus, anomalous origin from the pulmo-
nary artery and myocardial bridge (MB).
The diagnostic algorithm for athletes with suspect CCAA is shown
in Figure 12.
Anomalous coronary artery origin from a wrong aortic sinus
(either the right coronary artery from the left or the left coronary
artery from the right sinus) can present a variable course of the prox-
imal tract, i.e. pre-pulmonic, retro-aortic, intra-septal sub-pulmonic,
or inter-arterial and the latter is considered at risk of SCD.234,235
To the diagnosis, unfortunately, the ECG and even maximal exer-
cise test are often normal. If the index of suspicion is sufficiently high,
because of potential clinical markers (such as exertional syncope,
chest pain, or arrhythmias), the diagnosis can be defined non-inva-
sively by transthoracic (or transoesophageal) echocardiography as a
first step.235 It has been shown that visualization of the ostium and
Figure 11 Transesophageal echocardiogram of a 24-year old patient with bicuspid valve. Two-dimensional imaging showing bicuspid valve in sys-
tole characterized by the antero-posterior pattern (A); Real-time three-dimensional imaging showing the raphe between right and left coronary
cusps (red arrow, panel B); long-axis view of the aorta showing a marked dilation of the ascending aorta with a maximal diameter of 48 mm (C).
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proximal course of the left main and right coronary arteries is possi-
ble in over 98% and 80% of athletes.217
The failure to demonstrate that a CA originates from its proper
Valsalva sinus requires further anatomic confirmation with CT, CMR
angiography or coronary angiography based on age and risk profile
(Table 6; Figure 12).235,236 In patients with a clinical suspicion of
CCAA, the European Society of Cardiology recommends CT and
the American Heart Association either CT or CMR angiography, the
latter preferred due to radiation concerns.237,238
After the diagnosis, functional assessment of CCAA for clinical
management and advise relative to sport participation is challenging
in asymptomatic people. Aim of the functional assessment is detec-
tion of exercise-induced ischaemia. To the scope, nuclear scintigra-
phy and/or stress echocardiography and coronary angiography
should be performed. Intravascular ultrasound (IVUS) of the proxi-
mal vessel has been proposed to evaluate lesion severity based upon
the amount of hypoplasia and the degree of lateral compression;
finally, fractional flow reserve (FFR) assessment is also recom-
mended.235 Intravascular ultrasound and FFR should be performed
both at baseline and with pharmacological stress.
Myocardial bridge consists of a major epicardial CA, usually the left
anterior descending CA, coursing deep within the myocardium.239,240
Effort-induced ischaemia has been attributed to tachycardia, which
increases the myocardial oxygen requirement and reduces the coro-
nary flow occurring in diastole. Diagnosis of MB can be achieved non-
invasively by CT which can define the anatomic characteristics, such
as the length and depth of the intramyocardial course of the CA,
even if haemodynamic characteristics cannot be derived. Coronary
angiography confirms the diagnosis by showing the classic ‘milking
effect’ (i.e. a transient compression in systole, that can be accentuated
by intracoronary nitroglycerin injection). Intravascular ultrasound can
reveal the characteristic ‘half-moon’ sign and the extent of phasic
arterial compression, besides proximal plaque and negative arterial
remodelling.239
The major challenge, however, remains the criteria to guide man-
agement: crucial to risk stratification is the demonstration of exercise-
induced ischaemia.239,240 Reversible perfusion defects can be detected
by stress nuclear imaging (see Section 3.6). Alternatively, reversible
ischaemia due to MB can be detected by combined stress CMR perfu-
sion and wall motion imaging. Coronary physiological measurements
across a MB during pharmacological infusion are also valuable; i.e.
intracoronary Doppler can reveal the distinctive ‘fingertip’ phenom-
enon and iintracoronary pressure measurement with values of frac-
tional flow reserve (FFR) <0.75 suggests ischaemia.
5. Conclusion
This document offers a comprehensive overview of the cardiac phys-
iologic remodelling as well as the changes associated with pathologic
conditions, detectable in athletes by the most advanced imaging tech-
niques. The correct approach to the diagnosis and management of
cardiac pathologic conditions in athlete’s populations represents
nowadays a largely recognized clinical need for clinical cardiologists
and sport medicine specialists.
This document provides the clues for a timely and correct identifica-
tion of the most relevant cardiac diseases, according to the
most common clinical scenarios. Adherence to this document will help
clinicians to require imaging testing according to the recognized indica-
tions and provides the keys for appropriate interpretation of result, in
the context of the athlete’s gender, age, race, and sport participated.
Eventually, we are confident that appropriate use of cardiovascular
imaging techniques in the athlete’s population will facilitate a more
cost-effective cardiovascular evaluation, contributing to safer com-
petitive sport participation.
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Figure 12 Diagnostic algorithm for athletes with suspected coronary artery anomalies. The first step is represented by the evaluation of LV global
and regional function by echocardiography and identification of the coronary ostia from the parasternal short-axis view. The second step is the ana-
tomic evaluation of coronary arteries by Computed Tomography (CT), Magnetic Resonance Angiography (MRA) or coronary angiography. When
abnormalities are found, the third step is represented by functional studies, which may guide in understanding the clinical impact and help in the
patient management. CT, computed tomography; FFR, fractional flow reserve; LV, left ventricle; CMR, cardiac magnetic resonance.
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